ClinicalTrials.gg

Program

Amiodarone

Also written as “Amiodarone Hydrochloride Tablets”, “Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs” and “amiodarone”.

Its studies are mostly in Polycystic Kidney, Autosomal Dominant · Atrial Fibrillation, led by 3 companies.

Furthest: phase 4, since Aug 20, 20084 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Prism Pharmaceuticals20 open or runningphase 2since Aug 20, 2008Jan 8, 2007none ahead
Jemincare11 open or runningphase 1since Sep 12, 2025Sep 12, 2025none ahead
Johnson & Johnson10 open or runningphase 4since Oct 4, 2007Oct 4, 2007none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 8, 2007First study: phase 1 study in HealthyNew to Prism PharmaceuticalsPrism Pharmaceuticals · NCT00420953 · Canada
  2. Oct 4, 2007Johnson & Johnson's first study: phase 4 study in Atrial FibrillationNew to Johnson & JohnsonJohnson & Johnson · NCT00540787 · 112 enrolled · United States, France, Switzerland
  3. Aug 20, 2008Phase 2 study in Blood PressurePrism Pharmaceuticals · NCT00739193
  4. Sep 12, 2025Jemincare's first study: phase 1 study in Polycystic Kidney, Autosomal DominantNew to JemincareJemincare · NCT07181265 · 48 planned

TargetBeta

KCNH2 →read by rule
“HERG blocker”ChEMBL 37, by rule

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07181265Polycystic Kidney, Autosomal Dominant1Not yet recruitingJemincareApr 30, 202648
NCT00739193Blood Pressure2WithdrawnPrism PharmaceuticalsDec 20080
NCT00540787Atrial Fibrillation · United States, France, Switzerland4CompletedJohnson & JohnsonJun 1, 2006112
NCT00420953Healthy · Canada1CompletedPrism PharmaceuticalsApr 23, 2007

How it is read

Names in the registry

  • “Amiodarone Hydrochloride Tablets”, 1 entry
  • “Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs”, 1 entry
  • “amiodarone”, 1 entry
  • “Cordarone”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.